Scleromyxoedema: the importance of physical examination

BMJ Case Rep. 2018 Oct 12:2018:bcr2018227144. doi: 10.1136/bcr-2018-227144.

Authors

Sara Pipa¹, Juliana Sá², Ana Mondragão¹, António Marinho³

Affiliations

¹ Department of Internal Medicine, Centro Hospitalar de Vila Nova de Gaia/Espinho EPE, Vila Nova de Gaia, Portugal.
² Department of Internal Medicine, Centro Hospitalar Cova da Beira EPE, Covilha, Portugal.
³ Unit of Clinical Immunology, Centro Hospitalar Porto, Porto, Portugal.

No abstract available

Keywords: immunology; malignant disease and immunosuppression; skin.

Publication types

Case Reports

MeSH terms

Administration, Intravenous
Adult
Biopsy / methods
Diagnosis, Differential
Fibroblasts / metabolism*
Fibroblasts / pathology
Humans
Immunoglobulins / administration & dosage
Immunoglobulins / therapeutic use
Immunologic Factors / administration & dosage
Immunologic Factors / therapeutic use
Immunosuppressive Agents / administration & dosage
Immunosuppressive Agents / therapeutic use
Male
Mucins / metabolism*
Polychondritis, Relapsing / diagnosis
Polychondritis, Relapsing / drug therapy
Scleromyxedema / diagnosis*
Scleromyxedema / drug therapy
Scleromyxedema / immunology*
Scleromyxedema / pathology
Skin / immunology
Skin / pathology
Thalidomide / administration & dosage
Thalidomide / therapeutic use
Treatment Outcome

Substances

Immunoglobulins
Immunologic Factors
Immunosuppressive Agents
Mucins
Thalidomide